“PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials” (2023) Biomedical Research and Therapy, 10(12), pp. 6090–6102. doi:10.15419/bmrat.v10i12.851.